Support & Exhibitors
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases such as cancer, autoimmune conditions, and infectious diseases are diagnosed and treated. For more information, please visit adaptivebiotech.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
US Corporate Headquarters
Celgene Corporate Headquarters
86 Morris Avenue
Summit, NJ 07901
Tel: +1 908-673-9000
Fax: +1 908-673-9001
Janssen Pharmaceutica NV
At Janssen, helping patients overcome the challenges they face is our mission and privilege. We focus our efforts on discovering first of a kind medicines for cancers where there are limited treatment options and strive to make cancer a manageable, even curable condition.
Janssen Pharmaceutica NV
2340 Beerse, Belgium
Tel: +32 (0)14 60 21 11
Neopharm Israel is dedicated to the marketing and sales of premium ethical prescription products – pharmaceuticals, orphan drugs and biologic drugs.
Neopharm Israel is the exclusive representative and partner of leading multinational bio-pharma and consumer healthcare brands including Alexion, Celgene, Fresenius and many more
Sanofi Genzyme part of Sanofi dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
Genzyme Europe B.V.
1411 DD NAARDEN
TEL.: +31 (0) 35 699 1200
FAX: +31 (0)35 694 3214
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
The Association for Training, Education and Research in Hematology, Immunology and Transplantation (ATERHIT) is a non-for profit scientific organization based in Paris (France).
ATERHIT aims to promote clinical, translational and basis research in the fields of hematology, immunology and stem cell transplantation through direct or indirect support to research projects. It also organizes a board portfolio of educational activities with the goal to disseminate knowledge in its fields of interest and enhance collaborations among all stakeholders. ATERHIT provides support for students, fellows, junior doctors, nurses, and other healthcare professionals who wish to train or gain more experience in this field. The organization can distribute prizes to acknowledge some major achievements in these fields.
ATERHIT (Association for Training, Education, and Research in Hematology, Immunology and Transplantation)
Hôpital Saint Antoine, Service hématologie
184 rue du Faubourg Saint Antoine,
75012 Paris, France
Tel : 02 40 09 72 26 or 06 59 66 34 07
Email : firstname.lastname@example.org
Binding Site provides specialist diagnostic products to clinicians and laboratory professionals worldwide. We are dedicated to improving patient lives by delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders.
Binding Site’s Freelite® assays are supported by more than 18 years of clinical evidence, are the state of the art in free light chain testing and the ONLY serum free light chain test recommended by international and national guidelines for diagnosis and monitoring of multiple myeloma.
Visit Booth 1
Karyopharm Therapeutics is a clinical-stage pharmaceutical company, based in Newton, MA, USA, focused on the discovery, development and commercialization of novel, first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a central mechanism of oncogenesis via the inhibition of exportins specifically XPO1. Selinexor, Karyopharm’s lead candidate, has been administered to patients with hematologic malignancies or solid tumors in clinical trials worldwide. Karyopharm is currently preparing for its first potential U.S. commercial launch in 2019.
US-NON-08/18-00002 | ©Karyopharm Therapeutics Inc.
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds (PEnC).
Melflufen present program is intended as a treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical studies is to improve treatment outcomes with melflufen compared with established alternative drugs for patients with relapsed-refractory multiple myeloma. Melflufen will potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
Sebia a global diagnostic company, develops, manufactures and commercializes IVD tests and analyzers dedicated to cancer, diabetes and hemoglobin disorders. Sebia’s focus on capillary electrophoresis enables it to maintain a sustained R&D program, providing access to genuine innovations in any lab. More recently Sebia consolidated its large Myeloma product line, with two important additions, Hydrashift daratumumab, reagent to be used with the Hydragel IF test to mitigate the DARZALEX® interference, and two new generations sFLC assays, Seralite serum and Sebia FLC kappa and lambda kits.
Parc Technologique Léonard de Vinci
27 rue Léonard de Vinci
CP 8010 Lisses – 91008 EVRY Cedex
Tel: 01 69 89 80 80